Recent rapid biotechnological breakthroughs have led to the identification of complex and
unique molecular features that drive malignancies. Precision medicine has exploited next …

The combination of next-generation sequencing and advanced computational data analysis
approaches has revolutionized our understanding of the genomic underpinnings of cancer …

FoundationOne® CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-
approved companion diagnostic test to identify patients who may benefit from treatment in …

Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome-
and immune-targeted drugs that have transformed the outcomes of some malignancies …

Next-generation sequencing (NGS) can identify novel cancer targets. However, interpreting
the molecular findings and accessing drugs/clinical trials is challenging. Furthermore, many …

Immunotherapy induces durable responses in a subset of patients with cancer. High tumor
mutational burden (TMB) may be a response biomarker for PD-1/PD-L1 blockade in tumors …

Precision medicine focuses on DNA abnormalities, but not all tumors have tractable
genomic alterations. The WINTHER trial (NCT01856296) navigated patients to therapy on …

Importance Use of next-generation sequencing (NGS) to identify clinically actionable
genomic targets has been incorporated into routine clinical practice in the management of …

Purpose Fusions that involve neurotrophic-tropomyosin receptor kinase (NTRK) genes are
known drivers of oncogenesis. Therapies that target these ultra-rare, constitutionally active …

Background Recent advances are enabling delivery of precision genomic medicine to
cancer clinics. While the majority of approaches profile panels of selected genes or hotspot …